Drugs Made In America Acquisition Corp. Units Financial Flexibility Index
Drugs Made In America Acquisition Corp. Units financial flexibility index. Drugs Made In America Acquisition Corp. Units (DMAAU) has a Financial Flexibility Index of -0.02x as of March 2026. Free cash flow of $-125.18K (operating CF $-125.18K minus capex $0.00) represents 0% of total liabilities ($7.28 Million). See DMAAU cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Drugs Made In America Acquisition Corp. Units (2024–2025)
Financial flexibility index of Drugs Made In America Acquisition Corp. Units from 2024 to 2025. Historical Financial Flexibility Index trend for Drugs Made In America Acquisition Corp. Units across 2 annual periods. Check DMAAU operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
Drugs Made In America Acquisition Corp. Units Financial Flexibility Index by Year (2024–2025)
Drugs Made In America Acquisition Corp. Units financial flexibility index by year from 2024 to 2025. Year-by-year free cash flow to debt coverage for Drugs Made In America Acquisition Corp. Units. For the full cash flow conversion analysis, see cash flow conversion of Drugs Made In America Acquisition Corp. .
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.07x | $-539.19K | $-539.19K | $7.28 Million | ▲ +100.0% |
| 2024 | -216.50x | $-172.26K | $-172.26K | $795.67 | — |